Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- 1Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- 2The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- 3Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- 4Published in the Chemical Engineering Journal on April 1, 2025.
- 5Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.
Source
EurekAlert
Related News
•EurekAlert
AI Model Accurately Predicts Blood Loss Risk in Liposuction
A machine learning model predicts blood loss during high-volume liposuction with 94% accuracy.
•EurekAlert
AI-Driven CT Tool Predicts Cancer Spread in Oropharyngeal Tumors
Researchers have created an AI tool that uses CT imaging to predict the spread risk of oropharyngeal cancer, offering improved treatment stratification.
•EurekAlert
AI Model PRTS Predicts Spatial Transcriptomics From H&E Histology Images
Researchers developed PRTS, a deep learning model that infers single-cell spatial transcriptomics from standard H&E-stained tissue images.